Wall Street analysts expect Organon (OGN) to post quarterly earnings of $1.06 per share in its upcoming report, which indicates a year-over-year decline of 19.1%. Revenues are expected to be $1.63 billion, up 1.1% from the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company announces its earni ...

The latest trading session saw Organon (OGN) ending at $21.86, denoting a -1.84% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. Elsewhere, the Dow saw an upswing of 0.75%, while the tech-heavy Nasdaq appreciated by 2.64%. Shares of the pharmaceutical company witnessed a gain of 10.69% over the previous month, beating the performance of the Medical sector with its gain of 0.71% and the S&P 500's loss of 0.44%. Analysts and investors al ...

This pharmaceutical company is expected to post quarterly earnings of $1.11 per share in its upcoming report, which represents a year-over-year change of -15.3%. Revenues are expected to be $1.62 billion, up 1% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.96% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. ...

Investment Overview >$8bn. | Leverage ratio stable with 2023 year-end | --- | --- | --- | --- | --- | |---------------------------|----------|----------|----------|----------| | $ mil | Dec 2021 | Dec 2022 | Dec 2023 | Mar 2024 | | Cash and cash equivalents | 737 | 706 | 693 | 575 | | Gross Debt (1) | 9,134 | 8,913 | 8,760 | 8,714 | | Net Debt (1) | 8,397 | 8,207 | 8,067 | 8,139 | Furthermore, Organon's Established Brands division consists of >50 drugs whose patents are expiring, or have long since expired, ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Therefore, the Zacks rating upgrade for Organon basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in a company's future earnings potential, as reflected in earnings e ...

The pharmaceutical company's shares have seen an increase of 1.87% over the last month, surpassing the Medical sector's gain of 0.71% and falling behind the S&P 500's gain of 3.82%. Investors should also note any recent changes to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. The Zacks Rank system, running from #1 (Strong Buy) to #5 (St ...

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Organon possesses a Zacks Rank of #3 (Hold). Organon (OGN) ended the recent trading session at $19.93, demonstrating a -1.04% swing from the preceding day's closing price. This change lagged the S&P 500's 0.07% gain o ...

In the latest market close, Organon (OGN) reached $20.63, with a -0.77% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.04%, and the technology-centric Nasdaq increased by 0.49%. Prior to today's trading, shares of the pharmaceutical company had lost 0.91% over the past month. This has lagged the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. The upcoming earnings rel ...

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as w ...

Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Organon. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. The pharmaceutical company's shares have seen a decrease of 7.33% over the last month, not keeping up with the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59%. OGN's full-year Z ...